White Paper: Unlocking Durable Allogeneic Cell Therapy

New advances in immune evasion engineering are overcoming one of the biggest barriers in allogeneic cell therapy—immune rejection. With these advances, early clinical trials are starting to show long-term engraftment without chronic immunosuppression.

In this white paper, we review the latest clinical breakthroughs, the limitations of current autologous and encapsulation-based approaches, and how engineered iPSCs and genome editing technologies are creating scalable platforms for a new generation of therapies. Whether you work in biotech, translational research, or cell therapy development, this paper offers a clear look at the scientific and commercial inflection point shaping the future of regenerative medicine and engineered cell therapies.